Wo Wu Biological: Clinical Trial Summary Report of Artemisia Pollen Sublingual Drops after Market Launch

On the evening of July 22nd, Wuhan Biological announced that the company's product "Artemisia pollen allergen sublingual drops" has completed the "Long-term efficacy and safety evaluation of Artemisia pollen allergen sublingual drops for adult allergic rhinitis patients- a multicenter, open clinical trial", and has formed a clinical trial summary report. In this clinical trial, a total of 316 subjects were included in the analysis set, and the statistical analysis results showed that both the main efficacy indicators and secondary efficacy indicators had a significant improvement compared to the baseline Y0 peak period.